# OnCo record paper-capitello-291-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-capitello-291-nejm-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-capitello-291-nejm-2023" ;
  schema:name "CAPItello-291: capivasertib plus fulvestrant in hormone receptor-positive advanced breast cancer"@en ;
  schema:description "Adding the AKT inhibitor capivasertib to fulvestrant doubled the time to progression in advanced hormone receptor-positive breast cancer after aromatase inhibitor failure, with the largest gain in tumours with PIK3CA, AKT1 or PTEN alterations."@en ;
  schema:url <https://onco.cc/key-papers/paper-capitello-291-nejm-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2214131>, <https://pubmed.ncbi.nlm.nih.gov/37256976/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2214131> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Turner NC, Oliveira M, Howell SJ, et al." ;
  onco:cancers <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:drugs <https://onco.cc/drugs/capivasertib/> ;
  onco:trials <https://onco.cc/trials/capitello-291/> ;
  onco:journals <https://onco.cc/journals/nejm/> .